A prospective observational study of the inflammatory profile of Mepolizumab EXacerbations in participants with severe refractory eosinophilic asthma (the MEX study). (2021)

First Author: McDowell PJ

Abstract

No abstract provided

Bibliographic Information

Type: Journal Article/Review

Parent Publication: Lancet Respir Med. Accepted Dec 2020 (In Press)